On September 18, 2024, NanoVation Therapeutics entered into a multi-year partnership with Novo Nordisk to develop innovative genetic medicines targeting cardiometabolic and rare diseases. The collaboration combined NanoVation’s proprietary long-circulating lipid nanoparticle (lcLNP™) technology for RNA delivery outside the liver with Novo Nordisk’s expertise in genetic therapies.

The partnership focused on two lead base-editing therapy programs for rare genetic diseases, with potential expansion to five additional targets. NanoVation had been set to receive approximately US$600 million (around C$820 million) in up-front cash and milestone payments, plus tiered royalties on future product sales.

Farris represented NanoVation Therapeutics, while Ropes & Gray advised Novo Nordisk in this strategic partnership.